By Freddy Sebastian
Scilex Holding said a private investment group will purchase $100 million of its newly issued shares under a binding term sheet.
The investment will help Scilex expand its healthcare and medical technology initiatives and also support product development, acquisitions and strategic partnerships, working capital and operational growth, intellectual property expansion, as well as other general corporate purposes, the company said Monday.
The purchase price by iHolding Group for the Scilex shares is expected to be $15.00 apiece, which would represent about 6.7 million shares.
The investment is still subject to customary closing conditions.
Scilex focuses on acquiring, developing and commercializing non-opioid pain-management products to treat acute and chronic pain, and neurodegenerative and cardiometabolic diseases.
iHolding is headquartered in the Republic of Kazakhstan.
Write to Freddy Sebastian at freddy.sebastian@wsj.com